fenoldopam and Blood Pressure, High studies

Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.

Research Excerpts

Excerpt	Relevance	Reference
"Thirty-three patients with mild-to-moderate essential hypertension received either placebo or fenoldopam, a selective dopamine-1 agonist, by intravenous infusion at a fixed infusion rate ranging from 0."	9.09	Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. ( Ballard, K; Luther, RR; Mangoo-Karim, R; Polvino, W; Pool, JL; Shepherd, AM; Sunthornyothin, S; Taylor, AA, 1999)
"To compare the safeties and efficacies of IV fenoldopam (FNP) vs sodium nitroprusside (NTP) in severe acute hypertension."	9.08	Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group. ( Bednarczyk, EM; Dunbar, LM; Foulke, GE; Holcslaw, TL; Panacek, EA, 1995)
"Thirty-three patients with severe systemic hypertension defined as a diastolic blood pressure (DBP) > or = 120 mm Hg were randomized in a single-blind fashion to be treated with either intravenous fenoldopam mesylate (FNP) or sodium nitroprusside (NTP)."	9.07	Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension. ( Elliot, WJ; Green, JA; Murphy, MB; Nara, AR; Panacek, EA; Pilmer, BL; Rutherford, W, 1993)
"Fenoldopam mesylate stimulates adenyl cyclase in porcine ocular trabecular meshwork and raises intraocular pressure in humans."	9.07	Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans. ( Elliott, WJ; Geanon, J; Karnezis, TA; Murphy, MB; Silverman, RA; Tripathi, RC, 1991)
"We studied the renal effects of intravenous administration of fenoldopam mesylate, a dopamine-1 agonist, vs sodium nitroprusside following acute reduction of blood pressure (BP) in 11 patients with severe hypertension (supine BP, 168/124 to 252/135 mm Hg)."	9.06	Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. ( Halley, SE; White, WB, 1989)
"In an open-label study, we compared the efficacy and safety of intravenous infusion of fenoldopam mesylate with that of sodium nitroprusside in patients with severe hypertension or in hypertensive crisis."	9.06	Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. ( Gonzalez, FM; Huth, MM; Nguyen, BP; Reisin, E; Weed, SG, 1990)
"A series of studies were undertaken to assess the effect of oral fenoldopam, a specific DA1 dopamine receptor agonist on blood pressure and renal function in patients with mild essential hypertension."	9.06	Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension. ( Brown, J; Harvey, JN; Lee, MR; Worth, DP, 1986)
"Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension."	8.80	Fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies. ( Frishman, WH; Post, JB, 1998)
"We report the first case of the failure of fenoldopam for a pediatric patient with severe hypertension and renal failure."	7.73	Failure of fenoldopam to control severe hypertension secondary to renal graft rejection in a pediatric patient. ( Lechner, BL; Pascual, JF; Roscelli, JD, 2005)
"To evaluate the acute BP response to iv fenoldopam mesylate (FNP), 14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg) were studied in an open-label trial."	7.68	Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. ( Anderson, L; Bednarczyk, EM; Emmanuel, G; Gonzalez, FM; Green, JA; Hakki, AI; Munger, MA; Panacek, EA; Rutherford, WF; Weed, SG, 1990)
"Fenoldopam, a dopamine-1 (D1) agonist, was administered by a 6-h intravenous infusion to patients with refractory hypertension [diastolic blood pressure (DBP) greater than 115 mmHg while on triple therapy] in order to achieve a fall in DBP of 30 mmHg."	7.67	Renal effects of fenoldopam in refractory hypertension. ( Alcazar, JM; Astorga, A; Beck, T; Martinez, A; Miranda, B; Robles, RG; Rodicio, JL; Ruilope, LM; Sancho, J; Tovar, J, 1988)
" The effects of fenoldopam, an orally active, specific dopamine-1 receptor agonist, were studied in eleven patients with essential hypertension, using intra-arterial blood pressure recording and equilibrium gated radionuclide angiography."	7.67	Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension. ( Brigden, G; Caruana, MP; Heber, M; Raftery, EB, 1987)
"To determine the effects of dopamine-1 agonist therapy in severe hypertension, blood pressure, heart rate, catecholamines and left ventricular function were studied in 18 patients (10 with renal disease) with diastolic blood pressure greater than 120 mm Hg (range 124 to 160) after intravenous fenoldopam therapy."	7.67	Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. ( Gonzalez, FM; Katz, AM; McCabe, EJ; Radford, MJ; Weed, SG; White, WB, 1988)
"Fenoldopam seems to be an efficient alternative to nifedipine, especially because of its more rapid onset of action."	6.69	DA1-receptor stimulation by fenoldopam in the treatment of postcardiac surgical hypertension. ( Berger, J; Gombotz, H; Mahla, E; Metzler, H; Plaza, J, 1998)
" Fenoldopam caused an acute fall in blood pressure which lasted approximately 3 h after dosing and was associated with a reflex tachycardia."	6.67	A single dose study of the effects of fenoldopam and enalapril in mild hypertension. ( Freestone, S; Jeffrey, RF; Lee, MR; MacDonald, TM, 1991)
"Fenoldopam is a dopamine receptor (DA1 selective) agonist that is a systemic and renal vasodilator."	6.40	Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises. ( Aronson, S; Deeb, GM; Epstein, M; Levy, JH; Luther, RR; Oparil, S; Prielipp, R; Taylor, A, 1999)
" Fenoldopam and nitroprusside lowered blood pressure safely to an average pressure of 176/105 mm Hg; highly significant dose-response relations were found for the 13 patients receiving fenoldopam and the 15 receiving nitroprusside."	5.28	Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. ( Elliott, WJ; Fumo, MT; Gretler, DD; McCray, GR; Murphy, MB; Nelson, KS; Oliner, CM; Weber, RR, 1990)
"Thirty-three patients with mild-to-moderate essential hypertension received either placebo or fenoldopam, a selective dopamine-1 agonist, by intravenous infusion at a fixed infusion rate ranging from 0."	5.09	Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. ( Ballard, K; Luther, RR; Mangoo-Karim, R; Polvino, W; Pool, JL; Shepherd, AM; Sunthornyothin, S; Taylor, AA, 1999)
"To compare the safeties and efficacies of IV fenoldopam (FNP) vs sodium nitroprusside (NTP) in severe acute hypertension."	5.08	Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group. ( Bednarczyk, EM; Dunbar, LM; Foulke, GE; Holcslaw, TL; Panacek, EA, 1995)
"Thirty-three patients with severe systemic hypertension defined as a diastolic blood pressure (DBP) > or = 120 mm Hg were randomized in a single-blind fashion to be treated with either intravenous fenoldopam mesylate (FNP) or sodium nitroprusside (NTP)."	5.07	Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension. ( Elliot, WJ; Green, JA; Murphy, MB; Nara, AR; Panacek, EA; Pilmer, BL; Rutherford, W, 1993)
"Fenoldopam mesylate stimulates adenyl cyclase in porcine ocular trabecular meshwork and raises intraocular pressure in humans."	5.07	Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans. ( Elliott, WJ; Geanon, J; Karnezis, TA; Murphy, MB; Silverman, RA; Tripathi, RC, 1991)
"We studied the renal effects of intravenous administration of fenoldopam mesylate, a dopamine-1 agonist, vs sodium nitroprusside following acute reduction of blood pressure (BP) in 11 patients with severe hypertension (supine BP, 168/124 to 252/135 mm Hg)."	5.06	Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. ( Halley, SE; White, WB, 1989)
"In an open-label study, we compared the efficacy and safety of intravenous infusion of fenoldopam mesylate with that of sodium nitroprusside in patients with severe hypertension or in hypertensive crisis."	5.06	Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. ( Gonzalez, FM; Huth, MM; Nguyen, BP; Reisin, E; Weed, SG, 1990)
"A series of studies were undertaken to assess the effect of oral fenoldopam, a specific DA1 dopamine receptor agonist on blood pressure and renal function in patients with mild essential hypertension."	5.06	Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension. ( Brown, J; Harvey, JN; Lee, MR; Worth, DP, 1986)
"Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension."	4.80	Fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies. ( Frishman, WH; Post, JB, 1998)
" The novel DA1 receptor agonist fenoldopam is claiming a role in the management of hypertension, heart failure, and the preservation of renal function."	4.78	Dopamine and dopamine receptor agonists in cardiovascular therapy. ( Elliott, WJ; Murphy, MB, 1990)
" Abnormal renal sodium handling is considered a major contributing factor in hypertension associated with chronic ouabain treatment."	3.76	Dopamine-mediated inhibition of renal Na+/K+-ATPase in HK-2 cells is reduced by ouabain. ( Yuan, ZY; Zhang, YR, 2010)
"We report the first case of the failure of fenoldopam for a pediatric patient with severe hypertension and renal failure."	3.73	Failure of fenoldopam to control severe hypertension secondary to renal graft rejection in a pediatric patient. ( Lechner, BL; Pascual, JF; Roscelli, JD, 2005)
"Eight patients with stage I-II hypertension received a continuous IV infusion of the selective dopamine-1 agonist, fenoldopam, for up to 48 hours at rates from 0."	3.70	Sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: a dose-tolerability study. ( Ballard, KD; Luther, RR; Mangoo-Karim, R; Pool, JL; Taylor, AA, 1999)
" To determine whether PP(2A) expression and activity in the kidney are differentially regulated in genetic hypertension, we examined the effects of a D(1)-like agonist, fenoldopam, in renal cortical tubules and immortalized renal proximal tubule cells from normotensive Wistar-Kyoto rats (WKY) and SHR."	3.70	Renal protein phosphatase 2A activity and spontaneous hypertension in rats. ( Asico, LD; Eisner, GM; Felder, RA; Hopfer, U; Jose, PA; Yu, P, 2000)
"Fenoldopam (FE), a dopamine DA1-receptor agonist, has been introduced for treatment of arterial hypertension and heart failure and for preservation of renal function."	3.69	Effects of fenoldopam on intracranial pressure and hemodynamic variables at normal and elevated intracranial pressure in anesthetized pigs. ( Hennes, HJ; Jantzen, JP, 1994)
"To evaluate the acute BP response to iv fenoldopam mesylate (FNP), 14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg) were studied in an open-label trial."	3.68	Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. ( Anderson, L; Bednarczyk, EM; Emmanuel, G; Gonzalez, FM; Green, JA; Hakki, AI; Munger, MA; Panacek, EA; Rutherford, WF; Weed, SG, 1990)
" The effects of fenoldopam, an orally active, specific dopamine-1 receptor agonist, were studied in eleven patients with essential hypertension, using intra-arterial blood pressure recording and equilibrium gated radionuclide angiography."	3.67	Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension. ( Brigden, G; Caruana, MP; Heber, M; Raftery, EB, 1987)
"To determine the effects of dopamine-1 agonist therapy in severe hypertension, blood pressure, heart rate, catecholamines and left ventricular function were studied in 18 patients (10 with renal disease) with diastolic blood pressure greater than 120 mm Hg (range 124 to 160) after intravenous fenoldopam therapy."	3.67	Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. ( Gonzalez, FM; Katz, AM; McCabe, EJ; Radford, MJ; Weed, SG; White, WB, 1988)
" Fenoldopam, the first selective DA1-receptor agonist that can be administered to man, was infused intravenously in 17 patients with essential hypertension (mean blood pressure 152/101 mm Hg)."	3.67	Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam. ( Douglas, FL; Frederickson, ED; Goldberg, LI; McCoy, CE; Murphy, MB; Weber, RR, 1987)
"1 The pharmacokinetic properties of intravenous fenoldopam, a selective dopamine1-receptor agonist, were studied in 10 patients with essential hypertension."	3.67	Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients. ( Frederickson, ED; Goldberg, LI; McCoy, CE; Murphy, MB; Weber, RR; Ziemniak, JA, 1988)
"Fenoldopam, a dopamine-1 (D1) agonist, was administered by a 6-h intravenous infusion to patients with refractory hypertension [diastolic blood pressure (DBP) greater than 115 mmHg while on triple therapy] in order to achieve a fall in DBP of 30 mmHg."	3.67	Renal effects of fenoldopam in refractory hypertension. ( Alcazar, JM; Astorga, A; Beck, T; Martinez, A; Miranda, B; Robles, RG; Rodicio, JL; Ruilope, LM; Sancho, J; Tovar, J, 1988)
"Fenoldopam seems to be an efficient alternative to nifedipine, especially because of its more rapid onset of action."	2.69	DA1-receptor stimulation by fenoldopam in the treatment of postcardiac surgical hypertension. ( Berger, J; Gombotz, H; Mahla, E; Metzler, H; Plaza, J, 1998)
" Fenoldopam caused an acute fall in blood pressure which lasted approximately 3 h after dosing and was associated with a reflex tachycardia."	2.67	A single dose study of the effects of fenoldopam and enalapril in mild hypertension. ( Freestone, S; Jeffrey, RF; Lee, MR; MacDonald, TM, 1991)
" The following manuscript outlines the commonly used pharmacologic agents for perioperative BP including dosing regimens and adverse effect profiles."	2.66	Pharmacologic Control of Blood Pressure in Infants and Children. ( Krawczeski, CD; Naguib, A; Simsic, J; Tobias, JD, 2020)
"Perioperative hypertension is commonly encountered in patients that undergo surgery."	2.44	Perioperative hypertension management. ( Marik, PE; Varon, J, 2008)
"Essential hypertension is a major factor for myocardial infarction, heart failure and kidney failure."	2.43	A new approach for treatment of hypertension: modifying D1 dopamine receptor function. ( Felder, RA; Jose, PA; Zeng, C, 2006)
"Fenoldopam has no dopamine-2, alpha or beta-adrenergic activity and is 3."	2.41	[Fenoldopam: potential clinical applications in heart surgery]. ( Shorten, GD, 2001)
"Severe hypertension is a common clinical problem in the United States, encountered in various clinical settings."	2.41	The diagnosis and management of hypertensive crises. ( Marik, PE; Varon, J, 2000)
"Fenoldopam is a dopamine receptor (DA1 selective) agonist that is a systemic and renal vasodilator."	2.40	Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises. ( Aronson, S; Deeb, GM; Epstein, M; Levy, JH; Luther, RR; Oparil, S; Prielipp, R; Taylor, A, 1999)
" The possible applications of fenoldopam and suggested dosing regimens in children are reviewed."	2.40	Initial experience with fenoldopam in children. ( Pruitt, RD; Strauser, LM; Tobias, JD, 1999)
"Fenoldopam is a dopamine agonist that causes peripheral vasodilation via stimulation of dopamine 1 (D1) receptors."	2.40	Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. ( Brogden, RN; Markham, A, 1997)
"Initial use of dopamine agonists in the treatment of hypertension and its possible involvement in the etiology and maintenance of hypertension are discussed."	2.37	Dopamine receptors and hypertension. Physiologic and pharmacologic implications. ( Goldberg, LI, 1984)
" Infusion of FM at such low dosage appears also to be quite safe, even in CKD and hypertensive patients."	1.51	Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease. ( Busca, A; Casasco, M; Di Daniele, N; Ferrannini, M; Manca di Villahermosa, S; Marrone, G; Noce, A; Rovella, V; Sorge, R; Tesauro, M, 2019)
" As an active control, we used an equivalent antihypertensive dosage of captopril (10 mg/kg)."	1.30	Impaired renal vascular response to a D1-like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats. ( de Jong, PE; de Vries, PA; de Zeeuw, D; Kluppel, CA; Navis, G, 1999)
"Hyperactivity and hypertension are both expressed in the SHR."	1.29	Renal dopamine-1 receptors in hypertensive inbred rat strains with and without hyperactivity. ( Felder, RA; Hendley, ED; Ohbu, K; Yamaguchi, I, 1993)
" Fenoldopam and nitroprusside lowered blood pressure safely to an average pressure of 176/105 mm Hg; highly significant dose-response relations were found for the 13 patients receiving fenoldopam and the 15 receiving nitroprusside."	1.28	Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. ( Elliott, WJ; Fumo, MT; Gretler, DD; McCray, GR; Murphy, MB; Nelson, KS; Oliner, CM; Weber, RR, 1990)
" These findings suggest that in humans, fenoldopam may acutely override the dopaminergic antagonism of metoclopramide given in clinical dosage and that its cardiovascular and renal effects are not prostaglandin-mediated."	1.27	Cardiovascular and renal profile of acute peripheral dopamine1-receptor agonism with fenoldopam. ( Glück, Z; Gnädinger, MP; Jossen, L; Peheim, E; Weidmann, P, 1987)
"Fenoldopam (SK&F 82526) is a potent agonist at DA1 receptors, with much less agonist activity at the DA2 subtype or at alpha and beta adrenoceptors."	1.27	Hemodynamic effects of selective dopamine receptor agonists in the rat and dog. ( Blumberg, AL; DeMarinis, RM; Harvey, CA; Hieble, JP; Owen, DA; Valocik, RE, 1987)
"Pretreatment with metoclopramide (20 mg/kg) or SCH 23390 (30 micrograms/kg), a new selective dopamine-1 antagonist, significantly attenuated the vasodilator responses to fenoldopam in all three vascular beds."	1.27	Effects of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats. ( Lappe, RW; Todt, JA; Wendt, RL, 1986)

Research

Studies (84)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Percent Change MSNA Burst Frequency From Baseline to 60 Minutes

Timeframe	Studies, this research(%)	All Research%
pre-1990	20 (23.81)	18.7374
1990's	39 (46.43)	18.2507
2000's	18 (21.43)	29.6817
2010's	6 (7.14)	24.3611
2020's	1 (1.19)	2.80

Authors	Studies
Tobias, JD	2
Naguib, A	1
Simsic, J	1
Krawczeski, CD	1
Ye, Z	1
Lu, X	1
Deng, Y	1
Wang, X	1
Zheng, S	3
Ren, H	1
Zhang, M	1
Chen, T	1
Jose, PA	12
Yang, J	1
Zeng, C	5
Rovella, V	1
Ferrannini, M	1
Tesauro, M	1
Marrone, G	1
Busca, A	1
Sorge, R	1
Manca di Villahermosa, S	1
Casasco, M	1
Di Daniele, N	1
Noce, A	1
Pala, R	1
Mohieldin, AM	1
Shamloo, K	1
Sherpa, RT	1
Kathem, SH	1
Zhou, J	1
Luan, Z	1
Zheng, JG	1
Ahsan, A	1
Nauli, SM	1
Lu, Q	1
Yang, Y	1
Villar, VA	2
Asico, L	1
Jones, JE	1
Yu, P	3
Li, H	1
Weinman, EJ	1
Eisner, GM	7
Chen, Y	1
Asico, LD	6
He, D	1
Zhou, L	1
Varon, J	2
Marik, PE	2
Zhang, YR	1
Yuan, ZY	1
Mathur, VS	1
Luo, Y	2
Hopfer, U	5
Felder, RA	11
Wang, D	1
Welch, WJ	1
Wilcox, CS	1
Devlin, JW	1
Seta, ML	1
Kanji, S	1
Somerville, AL	1
Sanada, H	1
Yatabe, J	1
Sasaki, M	1
Watanabe, T	1
Elliott, WJ	6
Lechner, BL	1
Pascual, JF	1
Roscelli, JD	1
Andrews, P	1
Ackerman, DM	1
Blumberg, AL	2
McCafferty, JP	1
Sherman, SS	1
Weinstock, J	1
Kaiser, C	1
Berkowitz, B	1
Ventura, HO	1
Messerli, FH	1
Frohlich, ED	1
Kobrin, I	1
Oigman, W	1
Dunn, FG	1
Carey, RM	4
Goldberg, LI	3
Stote, RM	1
Dubb, JW	1
Townsend, LH	1
Rose, CE	1
Kaiser, DL	1
Chatziantoniou, C	2
Ruan, X	2
Arendshorst, WJ	2
Ohbu, K	3
Kaskel, FJ	2
Kinoshita, S	3
Bodmann, KF	1
Tröster, S	1
Clemens, R	1
Schuster, HP	1
Hennes, HJ	1
Jantzen, JP	1
Hendley, ED	1
Yamaguchi, I	1
Hill, AJ	1
Feneck, RO	1
Walesby, RK	1
Shusterman, NH	1
White, WB	4
Pilmer, BL	1
Green, JA	3
Panacek, EA	4
Elliot, WJ	1
Murphy, MB	8
Rutherford, W	1
Nara, AR	2
Hoekstra, JW	1
Bednarczyk, EM	3
Dunbar, LM	1
Foulke, GE	1
Holcslaw, TL	2
Krause, RS	1
Vachvanichsanong, P	1
Sela, S	1
Sidhu, A	3
O'Connell, DP	1
Ragsdale, NV	1
Boyd, DG	1
Brogden, RN	1
Markham, A	1
Post, JB	1
Frishman, WH	1
Gombotz, H	1
Plaza, J	1
Mahla, E	1
Berger, J	1
Metzler, H	1
Yao, LP	1
Li, XX	3
Yu, PY	1
Xu, J	4
Taylor, AA	2
Mangoo-Karim, R	2
Ballard, KD	1
Luther, RR	3
Pool, JL	2
Oparil, S	1
Aronson, S	1
Deeb, GM	1
Epstein, M	1
Levy, JH	1
Prielipp, R	1
Taylor, A	1
de Vries, PA	1
Navis, G	1
de Jong, PE	1
de Zeeuw, D	1
Kluppel, CA	1
Shepherd, AM	1
Polvino, W	1
Ballard, K	1
Sunthornyothin, S	1
Schafer, JA	1
Li, L	1
Sun, D	1
Albrecht, FE	3
Strauser, LM	1
Pruitt, RD	1
Robillard, JE	2
Shorten, GD	2
Murray, C	1
Li, X	1
Hackman, BB	1
Griffin, B	1
Mills, M	1
Ramanathan, KB	1
Chen, CJ	1
Lokhandwala, MF	1
Gretler, DD	2
Moscucci, M	1
Childers, RW	1
Karnezis, TA	1
Silverman, RA	1
Geanon, J	1
Tripathi, RC	1
MacDonald, TM	1
Jeffrey, RF	1
Freestone, S	1
Lee, MR	2
Girbes, AR	1
van Veldhuisen, DJ	1
Smit, AJ	1
Reisin, E	1
Huth, MM	1
Nguyen, BP	1
Weed, SG	4
Gonzalez, FM	4
Weber, RR	3
Nelson, KS	1
Oliner, CM	1
Fumo, MT	1
McCray, GR	1
Munger, MA	2
Rutherford, WF	2
Anderson, L	1
Hakki, AI	1
Emmanuel, G	1
Horton, R	2
Bughi, S	2
Jost-Vu, E	1
Antonipillai, I	2
Nadler, J	2
Beck, TR	1
VanCampen, M	1
Halley, SE	1
Manoogian, C	1
Ehrlich, L	1
Lappe, RW	1
Todt, JA	1
Wendt, RL	1
Harvey, JN	1
Worth, DP	1
Brown, J	1
Dupont, AG	2
Vanderniepen, P	2
Volckaert, A	2
Smitz, J	2
Vansteirteghem, AC	2
Six, RO	2
Glück, Z	1
Jossen, L	1
Weidmann, P	1
Gnädinger, MP	1
Peheim, E	1
Hieble, JP	1
Owen, DA	1
Harvey, CA	1
Valocik, RE	1
DeMarinis, RM	1
McCoy, CE	2
Frederickson, ED	2
Douglas, FL	1
Caruana, MP	1
Heber, M	1
Brigden, G	1
Raftery, EB	1
Radford, MJ	1
McCabe, EJ	1
Katz, AM	1
Ziemniak, JA	1
Ruilope, LM	2
Robles, RG	1
Miranda, B	2
Tovar, J	1
Alcazar, JM	2
Sancho, J	2
Rodicio, JL	2
Martinez, A	2
Astorga, A	1
Beck, T	1
García Robles, R	1
Tover, J	1
Astorga, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Investigating Mechanisms of Human Spinal Cord Stimulation for Purpose of Treating Restless Leg Syndrome[NCT03539081]		15 participants (Actual)	Interventional	2016-07-05	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Response will measured by peroneal nerve microneurography to the lower limb during epidural spinal cord stimulation in patients with chronic back pain.~Percent change MSNA burst frequency from baseline to 60 minutes" (NCT03539081)
Timeframe: Baseline to 60 minutes

Response Measurement of Thoracolumbar Epidural SCS in the Femoral Artery Blood Flow

Intervention	Percent change MSNA burst frequency (Mean)
Subjects With RLS	-29
Subjects Without RLS	-24

The response will be measured by Doppler ultrasound of the femoral artery during epidural spinal cord stimulation in patients with chronic back pain. (NCT03539081)
Timeframe: Baseline and 1.5 Hours

Article	Year
Pharmacologic Control of Blood Pressure in Infants and Children. Pediatric cardiology, 2020, Volume: 41, Issue:7 Topics: Adolescent; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Bl	2020
Perioperative hypertension management. Vascular health and risk management, 2008, Volume: 4, Issue:3 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Enalaprilat; Fenoldopam; Hemodynamics; Humans;	2008
The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. Reviews in cardiovascular medicine, 2003, Volume: 4 Suppl 1 Topics: Critical Illness; Dopamine Agonists; Fenoldopam; Humans; Hypertension; Kidney Diseases; Liver Transp	2003
[Involvement of dopamine receptor in the pathogenesis of hypertension and hypertensive target-organ damage]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 3 Topics: Animals; Dopamine; Dopamine Agonists; Fenoldopam; G-Protein-Coupled Receptor Kinase 4; Humans; Hyper	2004
Clinical features and management of selected hypertensive emergencies. Journal of clinical hypertension (Greenwich, Conn.), 2004, Volume: 6, Issue:10 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Emergency Treatment; Fenoldopam; Humans; Hyper	2004
A new approach for treatment of hypertension: modifying D1 dopamine receptor function. Cardiovascular & hematological agents in medicinal chemistry, 2006, Volume: 4, Issue:4 Topics: Antihypertensive Agents; Deoxyepinephrine; Dopamine; Dopamine Agonists; Fenoldopam; G-Protein-Couple	2006
Dopamine receptors and hypertension. Physiologic and pharmacologic implications. The American journal of medicine, 1984, Oct-05, Volume: 77, Issue:4A Topics: Animals; Benzazepines; Blood Pressure; Bromocriptine; Domperidone; Dopamine; Ergolines; Fenoldopam;	1984
Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs, 1997, Volume: 54, Issue:4 Topics: Antihypertensive Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Ele	1997
Fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies. Journal of clinical pharmacology, 1998, Volume: 38, Issue:1 Topics: Animals; Antihypertensive Agents; Dopamine Agonists; Drug Interactions; Emergencies; Fenoldopam; Hem	1998
Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises. American journal of hypertension, 1999, Volume: 12, Issue:7 Topics: Acute Disease; Animals; Antihypertensive Agents; Blood Pressure; Dopamine Agonists; Fenoldopam; Huma	1999
The diagnosis and management of hypertensive crises. Chest, 2000, Volume: 118, Issue:1 Topics: Antihypertensive Agents; Aortic Aneurysm; Aortic Dissection; Clonidine; Diazoxide; Enalaprilat; Fema	2000
Initial experience with fenoldopam in children. American journal of therapeutics, 1999, Volume: 6, Issue:5 Topics: Age Factors; Antihypertensive Agents; Body Weight; Brain Neoplasms; Child; Dopamine Agonists; Emerge	1999
[Fenoldopam: potential clinical applications in heart surgery]. Revista espanola de anestesiologia y reanimacion, 2001, Volume: 48, Issue:10 Topics: Acute Kidney Injury; Antihypertensive Agents; Coronary Artery Bypass; Diuretics; Dopamine Agonists;	2001
Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. The New England journal of medicine, 2001, Nov-22, Volume: 345, Issue:21 Topics: Animals; Antihypertensive Agents; Blood Pressure; Dopamine Agonists; Drug Synergism; Fenoldopam; Hum	2001
Dopamine and dopamine receptor agonists in cardiovascular therapy. Critical care medicine, 1990, Volume: 18, Issue:1 Pt 2 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Biological Availability; Blood Pressure;	1990
Clinical experience with intravenous fenoldopam. American journal of hypertension, 1990, Volume: 3, Issue:6 Pt 2 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Cardiovascular System; Chemical Phenomen	1990

Article	Year
Hemodynamic profile of intravenous fenoldopam in patients with hypertensive crisis. The Clinical investigator, 1993, Volume: 72, Issue:1 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acute Disease; Aged; Aged, 80 and over;	1993
A comparison of fenoldopam and nitroprusside in the control of hypertension following coronary artery surgery. Journal of cardiothoracic and vascular anesthesia, 1993, Volume: 7, Issue:3 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Atrial Function, Right; Blo	1993
Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. The American journal of medicine, 1993, Volume: 95, Issue:2 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Creatinine; Female; Fenoldopam; H	1993
Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension. Journal of clinical pharmacology, 1993, Volume: 33, Issue:6 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Blood Pressure; Female; Fen	1993
Fenoldopam for hypertensive emergencies. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 1995, Volume: 2, Issue:11 Topics: Antihypertensive Agents; Dopamine Antagonists; Emergencies; Fenoldopam; Humans; Hypertension; Prospe	1995
Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 1995, Volume: 2, Issue:11 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Blood Pressure; Female; Fenoldopam; Humans; Hypertens	1995
Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension (Dallas, Tex. : 1979), 1997, Volume: 29, Issue:1 Pt 1 Topics: Adult; Blood Pressure; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Female; Fenoldopa	1997
DA1-receptor stimulation by fenoldopam in the treatment of postcardiac surgical hypertension. Acta anaesthesiologica Scandinavica, 1998, Volume: 42, Issue:7 Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Catheterization,	1998
Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. American journal of hypertension, 1999, Volume: 12, Issue:9 Pt 1 Topics: Adolescent; Adult; Aged; Benzazepines; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dopami	1999
Comparative effects of fenoldopam mesylate and nitroprusside on left ventricular performance in severe systemic hypertension. The American journal of cardiology, 1992, Apr-01, Volume: 69, Issue:9 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Analysis of Variance; Blood Press	1992
Effects of intravenous fenoldopam (SK&F 82526-J) on blood pressure in severe hypertension. SK&F Fenoldopam Working Group. Cardiovascular drugs and therapy, 1992, Volume: 6, Issue:4 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Blood Pressure; Fenoldopam; Heart Rate;	1992
Electrocardiographic changes during acute treatment of hypertensive emergencies with sodium nitroprusside or fenoldopam. Archives of internal medicine, 1992, Volume: 152, Issue:12 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acute Disease; Adult; Dopamine Agents; E	1992
Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans. Clinical pharmacology and therapeutics, 1991, Volume: 49, Issue:3 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Blood Pressure; Dose-Response Rel	1991
A single dose study of the effects of fenoldopam and enalapril in mild hypertension. European journal of clinical pharmacology, 1991, Volume: 40, Issue:3 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Blood Pressure; Creatinine; Dopam	1991
Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension (Dallas, Tex. : 1979), 1990, Volume: 15, Issue:2 Suppl Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Blood Pressure; Blood Urea Nitrog	1990
Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Archives of internal medicine, 1989, Volume: 149, Issue:4 Topics: Adult; Benzazepines; Calcium; Creatinine; Diuresis; Dopamine Agents; Female; Fenoldopam; Ferricyanid	1989
Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension. British journal of clinical pharmacology, 1986, Volume: 21, Issue:1 Topics: Adult; Aldosterone; Benzazepines; Blood Pressure; Chromium Radioisotopes; Fenoldopam; Glomerular Fil	1986
Fenoldopam: effect on aldosterone secretion. British journal of clinical pharmacology, 1986, Volume: 21, Issue:2 Topics: Aldosterone; Benzazepines; Double-Blind Method; Fenoldopam; Humans; Hypertension; Metoclopramide; Mi	1986
Effect of fenoldopam on the aldosterone response to metoclopramide in man. Clinical endocrinology, 1986, Volume: 24, Issue:2 Topics: Aldosterone; Benzazepines; Clinical Trials as Topic; Double-Blind Method; Fenoldopam; Humans; Hypert	1986

Article	Year
In Utero Exposure to Fine Particulate Matter Causes Hypertension Due to Impaired Renal Dopamine D1 Receptor in Offspring. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 46, Issue:1 Topics: Animals; Blood Pressure; Cyclic N-Oxides; Diuresis; Down-Regulation; Female; Fenoldopam; Gestational	2018
Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease. Journal of nephrology, 2019, Volume: 32, Issue:1 Topics: Aged; Antihypertensive Agents; Arterial Pressure; Blood Flow Velocity; Female; Fenoldopam; Humans; H	2019
Personalized Nanotherapy by Specifically Targeting Cell Organelles To Improve Vascular Hypertension. Nano letters, 2019, 02-13, Volume: 19, Issue:2 Topics: Animals; Antihypertensive Agents; Cells, Cultured; Cilia; Drug Delivery Systems; Fenoldopam; Gold; H	2019
D5 dopamine receptor decreases NADPH oxidase, reactive oxygen species and blood pressure via heme oxygenase-1. Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:8 Topics: Animals; Blood Pressure; Dopamine Agonists; Fenoldopam; HEK293 Cells; Heme Oxygenase-1; Humans; Hype	2013
Gastrin and D1 dopamine receptor interact to induce natriuresis and diuresis. Hypertension (Dallas, Tex. : 1979), 2013, Volume: 62, Issue:5 Topics: Animals; Benzazepines; Diuresis; Dopamine Agonists; Dopamine Antagonists; Fenoldopam; Gastrins; Horm	2013
Dopamine-mediated inhibition of renal Na+/K+-ATPase in HK-2 cells is reduced by ouabain. Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:5-6 Topics: Blotting, Western; Cardiotonic Agents; Cell Culture Techniques; Cell Line; Cyclic AMP; Dopamine; Dop	2010
Perturbation of D1 dopamine and AT1 receptor interaction in spontaneously hypertensive rats. Hypertension (Dallas, Tex. : 1979), 2003, Volume: 42, Issue:4 Topics: Animals; Cell Line; Cells, Cultured; Dopamine Agonists; Fenoldopam; Hypertension; Kidney Tubules, Pr	2003
Aberrant D1 and D3 dopamine receptor transregulation in hypertension. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:3 Topics: Animals; Cell Line; Coronary Vessels; Dopamine Agonists; Fenoldopam; Humans; Hypertension; Kidney Tu	2004
Fenoldopam versus nitroprusside for the treatment of hypertensive emergency. The Annals of pharmacotherapy, 2004, Volume: 38, Issue:5 Topics: Antihypertensive Agents; Blood Pressure; Costs and Cost Analysis; Female; Fenoldopam; Hospital Bed C	2004
Failure of fenoldopam to control severe hypertension secondary to renal graft rejection in a pediatric patient. Military medicine, 2005, Volume: 170, Issue:2 Topics: Antihypertensive Agents; Child, Preschool; Fenoldopam; Graft Rejection; Humans; Hypertension; Kidney	2005
D1 dopamine receptor hyperphosphorylation in renal proximal tubules in hypertension. Kidney international, 2006, Volume: 70, Issue:6 Topics: Alkaline Phosphatase; Animals; Cell Line, Transformed; Cell Membrane; Cells, Cultured; Cyclic AMP; D	2006
Potential usefulness of renal vasodilators in hypertension and renal disease: SK&F 82526. Federation proceedings, 1983, Volume: 42, Issue:2 Topics: Animals; Benzazepines; Blood Pressure; Dogs; Fenoldopam; Hypertension; Isomerism; Kidney; Kidney Dis	1983
Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension. Circulation, 1984, Volume: 69, Issue:6 Topics: Administration, Oral; Adult; Benzazepines; Female; Fenoldopam; Hemodynamics; Humans; Hypertension; K	1984
Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. The Journal of clinical investigation, 1984, Volume: 74, Issue:6 Topics: Adult; Benzazepines; Blood Pressure; Fenoldopam; Heart Rate; Humans; Hypertension; Kidney; Middle Ag	1984
Defective G protein activation of the cAMP pathway in rat kidney during genetic hypertension. Proceedings of the National Academy of Sciences of the United States of America, 1995, Mar-28, Volume: 92, Issue:7 Topics: Angiotensin II; Animals; Blood Pressure; Cholera Toxin; Cyclic AMP; Fenoldopam; GTP-Binding Proteins	1995
Dopamine-1 receptors in the proximal convoluted tubule of Dahl rats: defective coupling to adenylate cyclase. The American journal of physiology, 1995, Volume: 268, Issue:1 Pt 2 Topics: Adenylyl Cyclases; Animals; Benzothiazoles; Blood Pressure; Colforsin; Cyclic AMP; Dopamine Agonists	1995
Interactions of cAMP-mediated vasodilators with angiotensin II in rat kidney during hypertension. The American journal of physiology, 1993, Volume: 265, Issue:6 Pt 2 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetylcholine; Angiotensin II; Animals;	1993
Effects of fenoldopam on intracranial pressure and hemodynamic variables at normal and elevated intracranial pressure in anesthetized pigs. Journal of neurosurgical anesthesiology, 1994, Volume: 6, Issue:3 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Anesthesia, General; Angiotensin II; Ani	1994
Renal dopamine-1 receptors in hypertensive inbred rat strains with and without hyperactivity. Hypertension (Dallas, Tex. : 1979), 1993, Volume: 21, Issue:4 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenylyl Cyclases; Aging; Animals; Benza	1993
Hypertensive urgency concern. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 1996, Volume: 3, Issue:6 Topics: Antihypertensive Agents; Emergencies; Fenoldopam; Humans; Hypertension	1996
Absence of DA1/DA2 dopamine receptor interactions in proximal tubules of spontaneously hypertensive rats. The American journal of physiology, 1996, Volume: 270, Issue:1 Pt 2 Topics: Affinity Labels; Animals; Binding Sites; Binding, Competitive; Dopamine Agonists; Dopamine Antagonis	1996
Fenoldopam--a new drug for parenteral treatment of severe hypertension. The Medical letter on drugs and therapeutics, 1998, May-22, Volume: 40, Issue:1027 Topics: Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Fenoldopam; Humans; Hyperten	1998
Dopamine D1 receptor and protein kinase C isoforms in spontaneously hypertensive rats. Hypertension (Dallas, Tex. : 1979), 1998, Volume: 32, Issue:6 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Angiotensin II; Animals; Biological Tran	1998
Sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: a dose-tolerability study. Journal of clinical pharmacology, 1999, Volume: 39, Issue:5 Topics: Adult; Antihypertensive Agents; Blood Pressure; Dopamine Agonists; Female; Fenoldopam; Heart Rate; H	1999
Impaired renal vascular response to a D1-like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats. Journal of cardiovascular pharmacology, 1999, Volume: 34, Issue:2 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Dopamine Agonists; Fenoldopam; Hemodyn	1999
The collecting duct, dopamine and vasopressin-dependent hypertension. Acta physiologica Scandinavica, 2000, Volume: 168, Issue:1 Topics: Animals; Arginine Vasopressin; Clozapine; Cyclic AMP; Dopamine; Dopamine Agonists; Dopamine Antagoni	2000
Dopamine(1) receptor, G(salpha), and Na(+)-H(+) exchanger interactions in the kidney in hypertension. Hypertension (Dallas, Tex. : 1979), 2000, Volume: 36, Issue:3 Topics: Animals; Benzazepines; Cyclic AMP; Dopamine Agonists; Fenoldopam; GTP-Binding Proteins; Guanosine 5'	2000
Renal protein phosphatase 2A activity and spontaneous hypertension in rats. Hypertension (Dallas, Tex. : 1979), 2000, Volume: 36, Issue:6 Topics: Animals; Benzazepines; Dopamine Agonists; Dopamine Antagonists; Fenoldopam; Hypertension; In Vitro T	2000
D(1) dopamine receptor regulation of NHE3 during development in spontaneously hypertensive rats. American journal of physiology. Regulatory, integrative and comparative physiology, 2001, Volume: 280, Issue:6 Topics: Aging; Animals; Blood Pressure; Dopamine Agonists; Fenoldopam; GTP-Binding Proteins; Hypertension; K	2001
[Regulation of NHE3 by D1 dopamine receptor during development of spontaneously hypertensive rats]. Zhonghua yi xue za zhi, 2001, May-10, Volume: 81, Issue:9 Topics: Aging; Animals; Blood Pressure; Dopamine Agonists; Fenoldopam; GTP-Binding Proteins; Hypertension; K	2001
An impairment of renal tubular DA-1 receptor function as the causative factor for diminished natriuresis to volume expansion in spontaneously hypertensive rats. Clinical and experimental hypertension. Part A, Theory and practice, 1992, Volume: 14, Issue:4 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Diuresis; Dopamin	1992
Dopamine agonists, a new perspective in cardiovascular therapy? The Netherlands journal of medicine, 1991, Volume: 39, Issue:1-2 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Deoxyepinephrine; Dopamine Agents; Fenol	1991
Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation, 1990, Volume: 81, Issue:3 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Dopamine Agents; Dose-Response Relations	1990
Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. Critical care medicine, 1990, Volume: 18, Issue:5 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Blood Pressure; Female; Fen	1990
Effect of dopamine on renal blood flow, prostaglandins, renin and electrolyte excretion in normal and hypertensive humans. American journal of hypertension, 1990, Volume: 3, Issue:6 Pt 2 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dopamine; Dopamine Agents; Dose	1990
A renal dopamine-1 receptor defect in two genetic models of hypertension. American journal of hypertension, 1990, Volume: 3, Issue:6 Pt 2 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenylyl Cyclases; Aging; Animals; Dopam	1990
Differential modulation of the renal proximal tubular DA-1 receptor by Gpp(NH)p and sodium in the spontaneously hypertensive rat. Journal of autonomic pharmacology, 1990, Volume: 10 Suppl 1 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dopamine Agents; Fenoldopam; Gu	1990
Comparative acute blood pressure reduction from intravenous fenoldopam mesylate versus sodium nitroprusside in severe systemic hypertension. The American journal of cardiology, 1989, Apr-15, Volume: 63, Issue:13 Topics: Adult; Aged; Benzazepines; Blood Pressure; Female; Fenoldopam; Ferricyanides; Heart Rate; Humans; Hy	1989
Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects. The Journal of clinical endocrinology and metabolism, 1989, Volume: 69, Issue:6 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Aldosterone; Blood Pressure	1989
Defective dopamine-1 receptor adenylate cyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rat. The Journal of clinical investigation, 1989, Volume: 84, Issue:6 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenylyl Cyclases; Affinity Labels; Anim	1989
Effects of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats. The Journal of pharmacology and experimental therapeutics, 1986, Volume: 236, Issue:1 Topics: Animals; Benzazepines; Blood Pressure; Fenoldopam; Heart Rate; Hypertension; Male; Metoclopramide; R	1986
Cardiovascular and renal profile of acute peripheral dopamine1-receptor agonism with fenoldopam. Hypertension (Dallas, Tex. : 1979), 1987, Volume: 10, Issue:1 Topics: Administration, Oral; Adult; Benzazepines; Blood Pressure; Catecholamines; Female; Fenoldopam; Heart	1987
Hemodynamic effects of selective dopamine receptor agonists in the rat and dog. Clinical and experimental hypertension. Part A, Theory and practice, 1987, Volume: 9, Issue:5-6 Topics: Anesthesia; Animals; Antihypertensive Agents; Benzazepines; Dogs; Female; Fenoldopam; Hemodynamics;	1987
Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam. Circulation, 1987, Volume: 76, Issue:6 Topics: Adult; Aldosterone; Benzazepines; Blood Pressure; Dose-Response Relationship, Drug; Female; Fenoldop	1987
Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension. British journal of clinical pharmacology, 1987, Volume: 24, Issue:6 Topics: Adult; Benzazepines; Blood Pressure; Female; Fenoldopam; Humans; Hypertension; Male; Middle Aged; Ra	1987
Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. Journal of the American College of Cardiology, 1988, Volume: 11, Issue:5 Topics: Adult; Aged; Benzazepines; Blood Pressure; Diuresis; Dopamine Antagonists; Drug Administration Sched	1988
Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients. British journal of clinical pharmacology, 1988, Volume: 25, Issue:1 Topics: Adult; Benzazepines; Blood Pressure; Dose-Response Relationship, Drug; Female; Fenoldopam; Humans; H	1988
Renal effects of fenoldopam in refractory hypertension. Journal of hypertension, 1988, Volume: 6, Issue:8 Topics: Adult; Benzazepines; Female; Fenoldopam; Humans; Hypertension; Kidney; Male; Middle Aged; Vasodilato	1988
[Effects of intravenous administration of fenoldopam on blood pressure and renal function in severe arterial hypertension]. Medicina clinica, 1988, Oct-15, Volume: 91, Issue:12 Topics: Adult; Benzazepines; Blood Pressure; Drug Evaluation; Female; Fenoldopam; Humans; Hypertension; Infu	1988

fenoldopam and Blood Pressure, High